Abstract
Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be “druggable” bidirectionally to either treat cancer or neuro-degenerative disorders.
Keywords: Mortalin, chaperone, cancer, aging, target, therapy, Hsp70, alleles, senescence, neuro-degenerative disorders.
Current Pharmaceutical Design
Title:Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Volume: 19 Issue: 3
Author(s): Custer C. Deocaris, Wen-Jing Lu, Sunil C. Kaul and Renu Wadhwa
Affiliation:
Keywords: Mortalin, chaperone, cancer, aging, target, therapy, Hsp70, alleles, senescence, neuro-degenerative disorders.
Abstract: Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be “druggable” bidirectionally to either treat cancer or neuro-degenerative disorders.
Export Options
About this article
Cite this article as:
C. Deocaris Custer, Lu Wen-Jing, C. Kaul Sunil and Wadhwa Renu, Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders, Current Pharmaceutical Design 2013; 19 (3) . https://dx.doi.org/10.2174/1381612811306030418
DOI https://dx.doi.org/10.2174/1381612811306030418 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Introduction (Transient Receptor Potential TRP Channels as Therapeutic Drug Targets: Next Round!)
Current Topics in Medicinal Chemistry Alternative Splicing and Tumor Progression
Current Genomics Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Recent Advances in Minimal Access Surgery for Infants and Children
Current Pediatric Reviews Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Quantum Chemical Studies on Ultimate Carcinogenic Metabolites from Polycyclic Aromatic Hydrocarbons
Current Medicinal Chemistry Review of Structures Containing Fullerene-C60 for Delivery of Antibacterial Agents. Multitasking model for Computational Assessment of Safety Profiles
Current Bioinformatics Prophylaxis of Cancer
Current Cancer Therapy Reviews